This is a routine insider sale of a small number of shares acquired through equity compensation. No material signal for the stock. Monitor for any larger insider sales or changes in insider sentiment in future filings.
RPRX drugs
RPRX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 15 $52.85entry
- T+1 · 6mo ago −1.48%α −1.41% · $52.07
- T+5 · 6mo ago +3.12%α +2.16% · $54.50
- T+20 · 5mo ago +2.69%α +0.57% · $54.27
- T+60 · 3mo ago +9.35%α +4.83% · $57.79
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Gregory Norden, an officer of Royalty Pharma, filed a Form 144 on May 14, 2026, indicating intent to sell 3,045 shares of common stock with an approximate market value of $161,385. The shares were acquired via vesting of restricted stock units on May 13, 2026, and the sale is a routine, small-dollar transaction relative to the company's $30.7B market cap.
Key Facts
- Filer: Gregory Norden (officer of Royalty Pharma)
- Proposed sale: 3,045 shares of common stock
- Approximate value: $161,385 (based on filing date price)
- Shares acquired via RSU vesting on May 13, 2026
- Sale intended to be executed through Merrill Lynch
- Transaction size is ~0.0005% of Royalty Pharma's $30.7B market cap
Financial Impact
Proceeds of approximately $161,385, representing a negligible fraction of market cap
Risk Factors
- Insider selling could be perceived negatively if it precedes a negative catalyst, but the small size here makes that unlikely
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001964306-26-000240 |
| Document: 0001964306-26-000240-index.html | 0001964306-26-000240 |
| Document: 0001964306-26-000240.txt | 0001964306-26-000240 |
Track record
23 reports on RPRX
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +15.20% at T+60 after the May 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry price pending
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $67.57 to $68.97 Now $68.53 +1.41% ▲ +2.07% −1.22% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $67.56 to $70.01 Now $68.53 +1.43% ▲ +3.63% +4.54% vs SPY
- Sep 30, 20266w ago Insider Cluster Bearish 5/10 Entry $57.63 to $56.21 Now $68.53 −18.91% ▲ +2.46% +3.77% vs SPY
- Sep 4, 202610w ago Press Release Bearish 5/10 Entry $60.59 to $58.47 Now $68.53 −13.10% ▲ +3.50% +2.38% vs SPY
- Aug 19, 202612w ago Insider Cluster Neutral 3/10 Entry $60.57 to $61.92 Now $68.53 +13.14% ▲ +2.24% +1.12% vs SPY
- Aug 12, 202613w ago 144 Neutral 3/10 Entry $58.56 to $60.58 Now $68.53 +17.02% ▲ +3.45% +5.41% vs SPY
- Aug 5, 202614w ago 8-K Bullish 6/10 Entry $57.75 to $59.22 Now $68.53 +18.66% ▲ +2.55% +2.19% vs SPY
- Jul 2, 202619w ago Insider Cluster Neutral 2/10 Entry $57.77 to $57.96 Now $68.53 +18.62% ▲ +0.33% −0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers